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Reduction in cardiovascular events after vascular
surgery with atorvastatin: A randomized trial
Anai E. S. Durazzo, MD, Fa´bio S. Machado, MD, Dimas T. Ikeoka, MD, Cla´udia De Bernoche, MD,
Maristela C. Monachini, MD, Pedro Puech-Lea˜o, MD, and Bruno Caramelli, MD, Sa˜o Paulo, Brazil
Objectives: This prospective, randomized, placebo-controlled, double-blind clinical trial was performed to analyze the
effect of atorvastatin compared with placebo on the occurrence of a 6-month composite of cardiovascular events after
vascular surgery. Cardiovascular complications are the most important cause of perioperative morbidity and mortality
among patients undergoing vascular surgery. Statin therapy may reduce perioperative cardiac events through stabilization
of coronary plaques.
Methods: One hundred patients were randomly assigned to receive 20 mg atorvastatin or placebo once a day for 45 days,
irrespective of their serum cholesterol concentration. Vascular surgery was performed on average 30 days after
randomization, and patients were prospectively followed up over 6 months. The cardiovascular events studied were death
from cardiac cause, nonfatal myocardial infarction, unstable angina, and stroke.
Results: Fifty patients received atorvastatin, and 50 received placebo. During the 6-month follow-up primary end points
occurred in 17 patients, 4 in the atorvastatin group and 13 in the placebo group. The incidence of cardiac events was more
than three times higher with placebo (26.0%) compared with atorvastatin (8.0%; P  .031). The risk for an event was
compared between the groups with the Kaplan-Meier method, as event-free survival after vascular surgery. Patients given
atorvastatin exhibited a significant decrease in the rate of cardiac events, compared with the placebo group, within 6
months after vascular surgery (P  .018).
Conclusion: Short-term treatment with atorvastatin significantly reduces the incidence of major adverse cardiovascular
events after vascular surgery. (J Vasc Surg 2004;39:967-76.)Among noncardiac surgical procedures, vascular sur-
gery is associated with the highest cardiovascular complica-
tion rates.1-11 This increased risk reflects the high likeli-
hood of underlying significant coronary artery disease in
patients undergoing these operations. Vascular procedures
are also associated with greater, often prolonged, hemody-
namic and cardiac stress.2-6
Several mechanisms may be responsible for the devel-
opment of coronary ischemia and myocardial infarction
(MI) in the operative setting. There is evidence that the
most important mechanism is coronary plaque instability
and rupture, which lead to thrombus formation and coro-
nary artery occlusion.1,12 Several interventionist studies
involving large populations have consistently demonstrated
the efficacy of 3-hydroxy-3-methylglutaryl coenzyme A
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doi:10.1016/j.jvs.2004.01.004reductase inhibitors (statin agents) for the primary and
secondary prevention of cardiovascular events.13-19 The
protective effects related to the use of statins seem to be
based on lipid-lowering and other properties of these
drugs, such as improvement in endothelial function and in
hemostasis and inflammation, which result in coronary
plaque stabilization.12,20,21 Despite this evidence, no ran-
domized prospective studies have been undertaken to ana-
lyze the effects of statins in the reduction of cardiovascular
morbidity and mortality in patients who must undergo
vascular surgery.
The current study was performed to evaluate whether
perioperative use of atorvastatin would reduce the inci-
dence of cardiovascular events, including death from car-
diac causes, nonfatal acute MI, ischemic stroke, and unsta-
ble angina, in patients undergoing vascular surgery.
METHODS
Study protocol. Between April 1999 and August
2000 we prospectively screened 227 consecutive patients
scheduled for elective noncardiac vascular surgery at the
Hospital das Clı´nicas, University of Sa˜o Paulo, Brazil. The
study protocol was approved and conducted in compliance
with the local ethics committee, informed consent regula-
tions, and International Conference on Harmonization
Good Clinical Practice guidelines.967
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tive noncardiac arterial vascular surgery, defined as aortic,
femoropopliteal, and carotid procedures. Exclusion criteria
included contraindications to the use of statins; severe
hepatic or renal disease, defined as baseline serum creati-
nine concentration greater than 2.0 mg/dL; pregnancy or
breast-feeding; current or previous use of drugs to treat
dyslipidemia; recent cardiovascular event, such as stroke,
MI, or unstable angina; serious infectious disease, uncon-
trolled at the time of the surgical intervention; human
immunodeficiency virus infection; and malignancy.
Study design. This prospective, randomized, place-
bo-controlled, double-blind clinical trial compared the ef-
fects of atorvastatin and placebo on the occurrence of a
6-month composite of cardiovascular events after noncar-
diac vascular surgery, including death from cardiac causes,
nonfatal acute MI, ischemic stroke, and unstable angina.
After giving written informed consent, eligible patients
were randomly assigned to receive either standard care plus
placebo or standard care plus atorvastatin, irrespective of
serum cholesterol concentration. A computer algorithm
was used in the randomization. The medication regimen
was 20 mg of atorvastatin or placebo once a day for 45 days.
Surgical intervention was performed during this period and
not earlier than 2 weeks after inclusion. Compliance was
assessed on the day of the surgical intervention, and was
considered effective if at least 75% of study medications
were taken before vascular surgery. For patients considered
noncompliant, an intention-to-treat analysis was adopted.
Perioperative -blocker use was recommended on the
basis of current guidelines. The criteria used to define
eligibility for perioperative -blocker use were coronary
artery disease, defined as previous MI, typical angina, or
atypical angina with positive results on stress test; or risk for
coronary artery disease, defined as the presence of at least
two of five factors, including age 65 years or older, hyper-
tension, current smoking, serum cholesterol level 240
mg/dL or greater, and diabetes.8,11
Anesthetic management and surgical technique were at
the discretion of the attending physicians, who were un-
aware of patient group assignment. Patients were moni-
tored for cardiovascular events for 6 months after surgery.
During the in-hospital phase of the study, electrocar-
diograms (ECGs) and measurements of lipid profile, he-
patic transaminase concentrations, and creatine kinase con-
centration (CK) were obtained before surgery. After the
surgery, ECGs were obtained and cardiac troponin levels
were determined daily until postoperative day 7. CK total
and CKMB (cardiac-bound) isoenzyme levels were deter-
mined every 6 hours on the day of surgery and on postop-
erative day 1, and later if acute coronary syndrome was
suspected. Neurologic examination was performed daily by
the investigators. When a diagnosis of ischemic stroke was
suspected, imaging was ordered and a neurologist was
consulted to confirm the diagnosis.
Outpatient follow-up was performed monthly over the
6 months after surgery. ECGs and measurements of lipid
profile were obtained 1, 3, and 6 months after surgery.Beyond 1 month after the surgical procedure, when the
45-day course of study medication was finished, and on the
basis of current guidelines, statin was recommended in all
patients with low-density lipoprotein (LDL)–cholesterol
level was greater than 100 mg/dL.
All data were collected by study investigators, and were
analyzed by a cardiovascular end point committee com-
prised of four cardiologists, one neurologist, and one vas-
cular surgeon, all unaware of patient group assignment.
Definition of cardiovascular events. The primary
end point was a composite of death from cardiac causes,
nonfatal acute MI, ischemic stroke, and unstable angina.
Death was considered due to cardiac causes if the
patient died of MI, cardiac arrhythmia, or congestive heart
failure caused primarily by a cardiac condition.22 The diag-
nosis of MI required elevated CK and CKMB, or cardiac
troponin concentration, when either of these conditions
was associated with at least one of two 12-lead ECG
changes, including development of new Q waves or new
persistent ST-T segment or T-wave changes; or evidence at
autopsy.22,23 Unstable angina was defined as severe chest
pain lasting for at least 30 minutes, unresponsive to stan-
dard therapeutic intervention, and associated with transient
ST-segment deviation of 0.05 mV or greater, new or T-
wave inversion 0.3 mV or greater without development of
Q waves, or CKMB elevation.24 The diagnosis of ischemic
stroke was made if signs or symptoms of ischemic stroke
were confirmed with imaging studies.
Sample size and statistical analysis. The sample size
was based on a previous study with -blockers in which a
cumulative incidence of cardiovascular events of 22% at 6
months was observed.8 We calculated that inclusion of 90
patients would be necessary to detect a reduction in the
incidence of the combined primary end points from 22% to
1%, with an alpha error level of 0.05, statistical power of
0.80, and 95% confidence interval.
Continuous variables, including age, duration of anes-
thesia, aortic clamping, and indicators of treatment effect,
such as medication uptake, lipid profile, aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) con-
centrations, and CK measurements, were evaluated by one-
sample Kolmogorov-Smirnov test for normality.
Normally distributed continuous variables are pre-
sented as mean  SD; differences between groups were
evaluated with the Student t test, with two-tailed P values
.05 considered significant.
Non-normally distributed continuous variables are pre-
sented as median values and corresponding 25th and 75th
percentiles; differences between groups were evaluated
with nonparametric tests (Mann-Whitney U test, two-sam-
ple Kolmogorov-Smirnov Test), with two-tailed P values
.05 considered significant.
Dichotomous data are presented as absolute numbers
and percentages. Differences in clinical characteristics be-
tween patient groups such as cardiac risk factors, history of
cardiac disease, preoperative medication, and concomitant
perioperative -bloker use, and surgical characteristics such
as type of vascular operation and anesthesia were evaluated
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 5 Durazzo et al 969with the Fisher exact test, with a two-tailed P value .05
considered significant.
Differences between the groups in the rate of occur-
rence of primary end points were evaluated with the Fisher
exact test, with a two-tailed P value .05 considered sig-
nificant. Event rates were further examined with the
Kaplan-Meier method and a corresponding log-rank
test; P  .05 was considered significant.
Analyses, performed according to intention to treat,
included a primary analysis with all 100 randomized pa-
tients and a secondary analysis excluding all randomized
patients who did not go on to surgery.
Safety assurance. All clinical and study investigators
were blinded to study group assignments throughout all
phases of the trial. One investigator, who was not directly
involved with patient care, was responsible for lipid profile,
hepatic transaminase concentration, and CK analysis dur-
ing the in-hospital stay. He monitored the safety of atorva-
statin administration, recommended protocol violation,
and atorvastatin withdrawal, when applicable, that is, AST
or ALT more than three times upper normal limit or CK
more than 10 times upper normal limit.25 With this strat-
egy, patient safety was assured, and investigators could not
infer, on the basis of lipid profile, the group assignment of
any patient.
RESULTS
Of the 227 consecutive patients assessed for eligibility,
127 were excluded. Ninety-one of these patients did not
meet the inclusion criteria: 22 needed urgent vascular
surgery and could not wait the period of time proposed by
the protocol, 26 were already receiving statins, 21 had renal
failure, 10 had a malignant disease, 2 had hepatic disease,
and 10 had a recent cardiovascular event; and 36 refused to
participate.
Of the 100 eligible patients, 50 were randomly assigned
to the atorvastatin group and 50 to the placebo group. Two
patients, both in the atorvastatin group, were considered
noncompliant. One patient had an adverse reaction to
atorvastatin, that is, rhabdomyolysis and elevated amino-
transferase levels, and the study medication was withdrawn.
In these patients, intent-to-treat analysis was adopted. A
flow diagram of the phases of this randomized trial is
presented in Fig 1.
Surgery was performed, on average, within 31 days
after medication was started. In six patients in the atorva-
statin group the surgical procedure was cancelled: three
patients refused the surgical procedure; two patients dem-
onstrated improvement in ischemic conditions of the lower
limbs; and one patient exhibited deterioration of the clini-
cal condition. In four patients in the placebo group the
surgical procedure was cancelled: two patients refused the
surgical procedure, and in two patients there was a change
in the surgical decision. Three patients included in this trial
to perform an infrainguinal bypass required a primary am-
putation, two below knee and one above knee.Patient characteristics according to study group are
presented in Table I. There were no significant differences
between the groups with respect to any of these variables.
Details of the surgical and anesthesia procedures are
presented in Table II. There were no significant differences
between the groups.
Details of compliance, tolerance, and other indicators
of treatment effect are presented in Table III. There were
no significant differences between the groups, except for a
significant increase in AST and ALT concentrations and a
significant reduction in total cholesterol and LDL choles-
terol values before and after therapy in the statin group.
LDL cholesterol concentration was significant lower in
the atorvastatin group than in the placebo group (P 
.0439) at 1 month after the surgical procedure, when the
45-day course of study medication had already ended.
There were no statistical differences between the groups in
terms of LDL cholesterol levels at 3 and 6 months after
surgery. Although 96.3% of patients in the atorvastatin
group and 84.6% of patients in the placebo group (P 
.1917) had been advised to start a statin treatment after 1
month after the surgical procedure, at the end of the
protocol only 13.8% of the atorvastatin group and 16.2% of
the placebo group were, in fact, taking statin therapy (P 
1.000)
Cardiac events. During the 6-month follow-up, a pri-
mary end point was observed in 17 patients, 4 patients in
the atorvastatin group and 13 patients in the placebo
group. In the atorvastatin group, one patient died of a
cardiac-related cause on postoperative day 68; and three
patients had a nonfatal acute MI, on the day of surgery and
postoperative days 2 and 10, respectively. In the placebo
group, two patients died of cardiac causes on postoperative
days 9 and 89; eight patients had a nonfatal acute MI, three
on the day of surgery, four on postoperative day 2, and one
on postoperative day 3; two patients had an ischemic
stroke, on postoperative days 5 and 141, respectively; and
in one patient unstable angina developed in the operating
room.
Of these 17 events, 16 occurred postoperatively and 1
occurred in the operating room. Thirteen of the 17 primary
end points (76,5%) were diagnosed during the in-hospital
phase of the study, including 10 detected during the first 2
days after surgery.
Fifty-six percent of patients in the atorvastatin group
and 64.0% in the placebo group used concomitant periop-
erative -blocker therapy (P  .541). Among -blocker
users (n  60), a primary end point occurred in 10; and
among non–-blocker–users (n  40), an end point oc-
curred in 7 (P  1.000). Among statin users, 28 (56.0%)
patients received concomitant perioperative -blocker
therapy, with a primary end point occurring in 3 patients;
and 22 (44.0%) patients did not receive concomitant peri-
operative -blocker therapy, with a primary end point
occurring in 1 patient. There were no significant differences
between the groups (P  .621).
The overall rate of combined end points of death from
cardiac causes, nonfatal acute MI, ischemic stroke, and
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with 8.0% in the atorvastatin group (P  .031; Table IV).
The risk for event occurrence was further compared
between the groups with the Kaplan-Meier method, as
event-free survival after surgery. Patients in the atorvastatin
group exhibited a significant decrease in the rate of cardiac
events, compared with the rate in the placebo group, within
6 months after surgery (P  .018; Fig 2.)
When the statistical analysis was performed only for the
90 patients who underwent surgery, the overall rate of
combined end points of death from cardiac causes, nonfatal
acute MI, ischemic stroke, and unstable angina was 28.3%
in the placebo group, compared with 9.1% in the atorvasta-
Fig 1. Flow diatin group (P  .030). The risk for an event was further
compared between the groups with the Kaplan-Meier
method, as event-free survival after surgery. The atorvasta-
tin group demonstrated a significant decrease in the rate of
cardiac events, compared with the rate in the placebo
group, within 6 months after surgery (P  .022).
DISCUSSION
In the United States alone, approximately 25 million
noncardiac surgical procedures are performed annually,
and many of these involve high-risk procedures or patients
at high risk.8 Perioperative cardiovascular morbidity and
mortality continue to be important clinical problems. At
of trial phases.gram
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cular protection in the perioperative period. Therefore the
question of whether short-term statin treatment can miti-
gate perioperative cardiovascular risk is important and new.
Table I. Patient characteristics by study group
Characteristic
Atorvastatin (n  5
n
Cardiac risk factors
Male gender 40
Age 65 y 33
Smoking
Current smoker 6
Ex-smoker
2 y 11
2 y 28
Never smoked 5
Diabetes mellitus 9
Hypertension 38
Dyslipidemia 32
History of cardiac disease
Myocardial infarction 15
Typical angina 8
Congestive heart failure 7
PTCA 2
CABG 5
Age (y)
Mean ( SD) 65.92  9.89
Range 36-86
Preoperative medications
Aspirin 19
Diuretics 14
Nitrates 5
-Blockers 28
Calcium channel blockers 4
ACE inhibitors 20
PTCA, Percutaneous transluminal coronary angioplasty; CABG, coronary a
*When a secondary analysis was performed only on data for 90 patients w
respect to any variable (data not shown).
Table II. Surgical procedures, by study group
Characteristic
Atorvasta
n
Vascular operation
Aortic repair (aneurysmal, occlusive,
dissection)
28
Infrainguinal arterial bypass 9
Carotid endarterectomy 6
Amputation 1
No operation 6
Type of anesthesia
General 39
Spinal 5
Duration of anesthesia (min)
Mean 317.27
Range 13
Aortic clamping when applicable (min)
Mean 68.43
Range 3
*When a secondary analysis was performed only on data for 90 patients w
respect to any variable (data not shown).Clinical trials of 3-hydroxy-methylglutaryl coenzyme A
reductase inhibitors, or statin therapy, demonstrate an im-
provement in cardiovascular end points and coronary ste-
nosis that is not completely explained by baseline or treated
Placebo (n  50)*
Pn %
39 78.0 1.000
32 64.0 1.000
11 22.0 .596
11 22.0
24 48.0
4 8.0
8 16.0 1.000
35 70.0 .653
31 62.0 1.000
14 28 1.000
3 6.0 .200
2 4.0 .160
4 8.0 .678
9 18.0 .388
68.38  9.53
46-83 .208
20 40.0 1.000
16 32.0 .827
2 4.0 .436
32 64.0 .541
8 18.0 .234
18 36.0 .837
bypass surgery; ACE, angiotensin converting enzyme.
derwent surgery, there was no significant differences between groups with
 50)* Placebo (n  50)*
P% n %
56.0 28 56.0 .906
18.0 11 22.0
12.0 5 10.0
2.0 2 4.0
12.0 4 8.0
88.6 33 71.7 .646
11.4 13 28.3
07.52 326.67  130.08 .714
0 249-390
2.15 67.82  48.91 .967
27-245
derwent surgery, there was no significant differences between groups with0)*
%
80.0
66.0
12.0
22.0
56.0
10.0
18.0
76.0
64.0
30.0
16.0
14.0
4.0
10.0
38.0
28.0
10.0
56.0
8.0
40.0
rtery
ho untin (n
 1
5-54
 4
0-224
ho un
al cho
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statins on clinical events may involve nonlipidic mecha-
nisms that modify endothelial function, inflammatory re-
Table III. Compliance, tolerance, and other indications o
Characteristic
Atorvastatin
(n  50)*
Medication uptake
Before surgery
Mean  SD 31.42  10.33
Range 2-45
Total period (d)
Median 45.00
25th-75th percentile 45.00-45.00
Total cholesterol (mg/dL)
Screening
Mean  SD 222.74  51.5
Range 139-464
Post-study drug
Mean  SD 161.11  46.3
Range 91-358
HDL (mg/dL)
Screening
Mean  SD 44.41  9.37
Range 26-69
Post-study drug
Mean  SD 39.47  10.07
Range 17-67
LDL (mg/dL)
Screening
Mean  SD 144.60  32.5
Range 66-234
Post–study drug
Mean  SD 88.75  30.72
Range 9-158
Triglycerides (mg/dL)
Screening
Median 128
25th-75th percentile 87.00-178.00
Post–study drug
Median 117
25th-75th percentile 89.5-157.00
AST (U/L)
Screening
Mean  SD 22.39  7.71
Range 10-58
Post–study drug
Median 21.00
25th-75th percentile 18.00-25.00
ALT (U/L)
Screening
Median 18.00
25th-75th percentile 14.00-23.50
Post–study drug
Median 20.00
25th-75th percentile 15.00-26.25
Creatine kinase (U/L)
Screening
Median 79.00
25th-75th percentile 49.75-112.00
Post–study drug
Median 73.00
25th-75th percentile 47.00-90.75
HDL, High-density lipoprotein; LDL, low-density lipoprotein; AST, aspart
*Similar to the primary analysis, when a secondary analysis was performed on
a significant difference between groups were post–study drug values for totsponses, plaque stability, and thrombus formation. Non-
lipid properties can be observed earlier than lipid effects in
patients using statin agents; short-term treatment with
tment effect, by study group
Placebo
(n  50)* P
29.28  9.22 .277
14-45
45.00 .800
45.00-45.00
214.52  53.25 .435
135-377
207.04  58.00 .0001
103-399
43.38  13.42 .659
17-89
38.69  9.59 .704
22-58
139.65  41.62 .518
79-268
133.31  47.09 .0001
24-306
156.18 .733
95.75-198.25
123 .552
94.50-193.00
19.84  6.64 .083
10-49
19.00 .037
16.00-22.00
15.00 .259
12.00-19.00
15.00 .002
12.00-20.00
66.00 .318
41.50-105.00
57.00 .137
38.00-98.50
nsaminase; ALT, alanine transaminase.
data for 90 patients who underwent surgery, the only variables that showed
lesterol, LDL, AST, and ALT (data not shown).f trea
9
7
8
ate tra
ly on
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endothelial function, and in hemostasis and inflammation.
Coronary plaque rupture and erosions are recognized pre-
cipitants of thrombosis or acute MI, unstable angina, and
sudden death in the operative and nonoperative set-
ting.1,12-19 A variety of physiologic perturbations induced
by the perioperative status may precipitate this plaque
instability and thrombosis. These include increased sympa-
thetic tone, anemia, pain, temperature fluctuation, activa-
tion of the coagulation system, and abrupt changes in
metabolic, hemodynamic, and electrolytic parameters.12
The progression of plaques during surgery is not predict-
able, making systemic medical therapy for plaque stability
with statin agents an attractive option.1,12,20,21
Despite its indisputable benefit in the prevention of
cardiovascular events, at present there is only one previous
retrospective study recently published and no randomized
prospective studies that analyzed the effect of statin agents
on perioperative cardiovascular mortality and morbidity in
patients undergoing vascular surgery. Poldermans et al1
performed a case-control study to evaluate the association
between statin use and perioperative mortality. In this
retrospective study statin therapy was significantly less com-
mon in patients than in control subjects (8% vs 25%; P 
.001), reducing perioperative mortality in patients under-
going major vascular surgery. As compared with nonusers,
patients receiving statin therapy were at more than fourfold
reduced risk.1
The results of the present randomized prospective trial
demonstrate that perioperative administration of atorvasta-
tin is associated with a significant reduction in the com-
bined incidence of cardiovascular events, including death
from cardiac causes, nonfatal acute MI, ischemic stroke,
and unstable angina, in patients undergoing vascular sur-
gery. The observed treatment effect was not attributable to
differences between the two groups with respect to clinical,
surgical, therapeutic, or anesthesia characteristics. This
treatment effect corroborated the early evidence of the
beneficial effect of statin therapy recently demonstrated by
Poldermans et al1 in their retrospective trial.
The 26.0% rate of perioperative events in the standard
care group is consistent with the results of previous studies
that estimated these rates at 4,5% to 34%.1-9 At first glance,
the 8.0% rate of perioperative events in the atorvastatin
group seems high compared with 0% and 3.4% observed in
Table IV. Primary end points for study group
Characteristic
Atorvastatin
(n  50)
Placebo
(n  50)
Pn % n %
Death from cardiac causes 1 2.0 2 4.0 1.000
Nonfatal acute myocardial
infarction
3 6.0 8 16.0 .199
Unstable angina — 1 2.0 1.000
Ischemic stroke — 2 4.0 .495
Combined end point 4 8.0 13 26.0 .031patients given -blocker therapy in the studies by Mangano
et al8 and Poldermans et al.9 Mangano et al8 performed a
randomized, double-blind, placebo-controlled trial to
compare the effect of atenolol with that of placebo on
mortality and cardiovascular morbidity in patients who
underwent noncardiac surgery. Among the operations per-
formed, only 40% were vascular, which are associated with
the highest risk for cardiovascular complications. More-
over, the 100% rate of event-free survival at 6 months in the
atenolol group was related to the 192 patients who survived
to hospital discharge. In the present trial most primary end
points were detected during the hospital stay, which may
explain our higher rate of cardiovascular events. Polder-
mans et al9 studied the perioperative use of bisoprolol in
elective major vascular surgery. The study was confined to
patients with at least one cardiac risk factor and evidence of
inducible myocardial ischemia at dobutamine echocardiog-
raphy. Their follow-up time (30 days) differed from ours,
which can explain the lower incidence of perioperative
events. Also different from those studies, in our study
cardiac troponin was measured and used for the diagnosis
of MI. Both Q and non-Q-wave infarctions were consid-
ered end points, which could also have contributed to our
higher event rate.
In the present study 56% of patients in the atorvastatin
group and 64% in the placebo group used concomitant
perioperative -blocker therapy. No statistical difference
showing the beneficial effect of concomitant use of statin
and -blocker was found, probably because of the small
sample size. Although the cardioprotective effect of
-blocker was confirmed in their statin study, Poldermans
et al1 also missed the beneficial effect of concomitant use of
-blocker and statin, probably because of lack of statistical
Fig 2. Event-free survival in the 6 months after vascular surgery,
according to study group. Outcome measures included death from
cardiac causes, nonfatal acute myocardial infarction, ischemic
stroke, and unstable angina. Rate of event-free survival at 6 months
(180 days) was 91.4% in the atorvastatin group and 73.5% in the
placebo group (P  .018).
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mon (inflamation), but -blockers may particularly influ-
ence myocardial supply and demand mismatch, whereas
statin may affect coronary plaque stabilization. Patients
undergoing vascular surgery will probably benefit from
receiving both medications during the perioperative pe-
riod; however, further investigations are recommended to
clarify these issues.
The atorvastatin dose of 20 mg once a day was used as
an equivalent dose, at least in terms of cholesterol reduc-
tion, of others statins used in previous studies for primary
and secondary prevention of cardiovascular events in large
populations.13-17 To ensure that patients would be receiv-
ing the treatment at the time surgery was performed and
that endothelial function had already improved, promoting
plaque stabilization, the 45-day course of medication was
chosen. Among statin users in the Poldermans et al1 statin
study, the duration of statin therapy was apparently shorter
in patients than in control subjects; nonetheless, the possi-
bility of a beneficial effect after a short period of statin
treatment could not be excluded. In the current study the
beneficial effect of statin treatment was observed after a
short period; the full proposed course of statin treatment
was 45 days. Among statin users, the duration of statin
therapy had no influence on the incidence of cardiovascular
events. However, this length of time was homogeneous;
almost all patients received the full intended 45-day course
of statin treatment. Therefore further investigations are
needed to evaluate timing, dosage, and duration of therapy
in more detail.
The rationale for the prolonged cardiac protection
offered by perioperative statin use may be in part the same
as for perioperative -blokade; that is, long-term adverse
outcomes after noncardiac surgery are significantly more
frequent in patients who have had one or more episodes of
perioperative myocardial ischemia.8 In our study, 13 of the
17 primary end points (76,5%) were detected during the
in-hospital phase of the study. In addition, nonlipid prop-
erties promoting plaque stabilization can be observed ear-
lier than lipid effects in patients given statin therapy and are
maintained longer after discontinuation of the drug.
Angiotensin converting enzyme inhibitors were used
by 40.0% of patients in the atorvastatin group and by 36.0%
patients in the placebo group. Thirty-eight percent of pa-
tients in the atorvastatin group and 40.0% in the placebo
group used concomitant perioperative aspirin therapy. In-
asmuch as patients were scheduled for major vascular sur-
gery, they were advised to withhold aspirin for at least 1
week before surgery, especially if they were to undergo
aortic repair. Aspirin was prescribed during the postopera-
tive period, as soon as possible on the basis of findings at
clinical evaluation. In the current study, short-term treat-
ment with atorvastatin significantly reduced the incidence
of cardiovascular events after vascular surgery and provided
additional benefit to -blockade, angiotensin converting
enzyme inhibitors, and aspirin.
The analysis of cardiac events showed significant differ-
ences between the atorvastatin and placebo groups, amongall 100 randomized patients (P  .018) and when the
analysis was performed only on data for the 90 patients who
underwent surgery (P  .022), both demonstrating the
benefit of a short-term perioperative use of atorvastatin.
CONCLUSION
The results of this randomized prospective trial indicate
that the incidence of cardiovascular events in the first 6
months after surgery, including death from cardiac causes,
nonfatal acute MI, ischemic stroke, and unstable angina,
can be reduced with perioperative use of atorvastatin in
patients who must undergo vascular surgery, irrespective of
their serum cholesterol concentration.
On the basis of clinical data from this study, there is
clear benefit to the use of atorvastatin in the perioperative
phase. These results await confirmation with a multicenter
randomized clinical trial.
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Janet T. Powell, MD, PhD
Few patients with peripheral arterial disease have a disease-free
coronary circulation.1 Reconstructive procedures impose further
stress on the diseased coronary circulation, and cardiac morbidity
and mortality are recognized complications of vascular surgery.
The article by Durazzo et al in this issue of The Journal makes the
exciting suggestion that a short course of perioperative statins
could minimize these complications.
Before we all rush into new statin protocols, it is prudent to
examine the evidence carefully. One hundred patients, scheduled
for elective vascular procedures, were randomized to receive either
20 mg of atorvastatin or placebo, and the trial was designed to
show a reduction in postoperative cardiovascular events from 22%
to 1% within 6 months. This was a challenging target to set,
because even in patients at the highest cardiac risk undergoing
vascular surgery under general anaesthesia the perioperative car-
diovascular event rate is 34%.3 In the trial by Durazzo et al, 2
patients in the placebo group underwent more procedures under
spinal anaesthesia, 13 of 46 vs 5 of 44 in the atorvastatin group.
Therefore the incidence of events in the placebo group (26%) was
very high, unless spinal anesthesia was used, because these patients
were more likely to have American Society of Anesthesiologists
grade III and IV disease. In contrast, statin treatment reduced the
incidence of cardiovascular events to 8%, a result that just achieved
significance P .031. The excess events in the placebo group were
predominantly myocardial infarction and stroke. Survival analysis
showed a more convincing benefit in favor of atorvastatin treat-
ment. Confirmation of these results from other trials is awaited
eagerly.
So there is cautious optimism for an effective, simple, safe, new
treatment to minimize perioperative cardiac morbidity and mor-
tality after vascular surgery. Further support for this optimism
comes from retrospective analyses of in-hospital mortality after
vascular surgery and from late mortality after successful aorticaneurysm repair.4,5 Statin therapy was more common in patients
discharged after vascular surgery than in those who died in hospital
(25% vs 8%; P .001).4 Late cardiovascular deaths after aneurysm
repair were reported in 9% of statin users compared with 38% in
nonusers.5 All of these studies reported that the benefit of statins is
independent of the use of -blockers.
How do statins produce these effects? Reduction of serum
lipid concentrations is an unlikely explanation for immediate ben-
eficial effects of statins on perioperative morbidity and mortality.
Two studies started with the hypothesis that statins exert their
beneficial perioperative effect by plaque stabilization.2,4 Statin
therapy also reduces postprocedural myocardial infarction and
death after percutaneous coronary intervention.6 In this context,
analysis of the serum C-reactive protein concentration indicated
that statins exert their effect by an anti-inflammatory mechanism,
statin therapy having most marked benefit in patients with the
highest preprocedural C-reactive protein concentrations.6
It is disappointing that only a minority of patients (15%) in the
trial by Durazzo et al2 continued to receive statin therapy after 45
days. Vascular surgeons must not ignore the mounting evidence
that statins benefit the cardiovascular health and survival of all
patients with peripheral arterial disease.7
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